VIA
TNGX icon

Virtus Investment Advisers’s Tango Therapeutics TNGX Stock Holding History

Virtus Investment Advisers’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$331K Sell
10,576
-18,587
-64% -$460K 0.08% 359
2026
Q1 		$610K Buy
29,163
+711
+2% +$9.9K 0.17% 192
2025
Q4 		$252K Buy
28,452
+5,920
+26% +$51K 0.07% 325
2025
Q3 		$189K Buy
22,532
+3,912
+21% +$26.5K 0.05% 259
2025
Q2 		$95.3K Sell
18,620
-38,979
-68% -$96.4K 0.03% 352
2025
Q1 		$78.9K Buy
+57,599
New +$141K 0.02% 449

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Virtus Investment Advisers's TNGX Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Tango Therapeutics (TNGX) stake by 64% in Q2 2026, selling an estimated $460K and leaving 10,576 shares worth $331K. The position accounts for 0.08% of the portfolio, ranked #359.

Virtus Investment Advisers first reported a position in TNGX in Q1 2025 and has held it in 6 quarters since. The position peaked at $610K in Q1 2026. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Virtus Investment Advisers held 10,576 shares of Tango Therapeutics worth $331K as of Q2 2026.
  • Virtus Investment Advisers sold 18,587 Tango Therapeutics shares in Q2 2026, an estimated $460K.
  • Tango Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #359 holding.
  • Virtus Investment Advisers first reported a position in Tango Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Virtus Investment Advisers's Tango Therapeutics position peaked at $610K in Q1 2026.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.